Table 3.
Comparison of target gene expression according to oncological outcomes (cancer-specific death and recurrence).
| Cancer-Specific Death | |||||
|---|---|---|---|---|---|
| FPKM (Mean ± SD) | RCC with Cancer-Specific Death (n = 8) | RCC without Cancer-Specific Death (n = 16) | p-Value a | Multivariate OR (95% CI) | p-Value b |
| MOCOS | 16.4 ± 12.5 | 5.4 ± 12.4 | 0.054 | - | 0.093 |
| RGPD8 | 47.6 ± 38.4 | 12.2 ± 17.5 | 0.036 | 1.048 (1.006–1.093) | 0.026 |
| BAIAP2L1 | 7.5 ± 4.0 | 3.2 ± 2.2 | 0.019 | 1.553 (1.088–2.215) | 0.015 |
| DDX11 | 34.3 ± 13.4 | 17.5 ± 9.3 | 0.002 | 1.130 (1.025–1.245) | 0.014 |
| SLC16A9 | 1.3 ± 2.3 | 9.9 ± 8.2 | 0.001 | 0.585 (0.362–0.946) | 0.029 |
| FRAS1 | 2.4 ± 2.5 | 11.4 ± 7.4 | <0.001 | 0.741 (0.567–0.967) | 0.028 |
| NPR3 | 3.1 ± 3.4 | 10.3 ± 8.0 | 0.006 | - | 0.058 |
| AQP1 | 11.3 ± 12.8 | 30.2 ± 19.7 | 0.023 | 0.926 (0.859–0.997) | 0.042 |
| TMEM38B | 1.9 ± 1.2 | 7.2 ± 2.9 | <0.001 | 0.277 (0.091–0.841) | 0.024 |
| PRUNE2 | 20.1 ± 8.5 | 41.3 ± 20.5 | 0.002 | 0.921 (0.854–0.993) | 0.032 |
| Recurrence | |||||
| FPKM (Mean ± SD) | RCC with Recurrence (n = 7) | RCC without Recurrence (n = 17) | p-Value a | Multivariate OR (95% CI) | p-Value b |
| MOCOS | 9.5 ± 6.6 | 8.9 ± 15.4 | 0.921 | - | 0.917 |
| RGPD8 | 65.5 ± 25.9 | 6.9 ± 6.0 | 0.001 | - | 0.996 |
| BAIAP2L1 | 6.8 ± 3.0 | 3.7 ± 3.4 | 0.048 | - | 0.066 |
| DDX11 | 36.0 ± 10.2 | 17.8 ± 10.6 | 0.001 | 1.140 (1.029–1.264) | 0.012 |
| SLC16A9 | 1.5 ± 2.1 | 9.3 ± 8.3 | 0.002 | - | 0.056 |
| FRAS1 | 3.1 ± 2.8 | 10.6 ± 7.8 | 0.002 | - | 0.051 |
| NPR3 | 2.9 ± 2.5 | 9.9 ± 8.1 | 0.004 | - | 0.073 |
| AQP1 | 12.7 ± 13.0 | 28.5 ± 20.3 | 0.071 | - | 0.090 |
| TMEM38B | 2.5 ± 1.5 | 6.6 ± 3.4 | 0.001 | 0.579 (0.355–0.944) | 0.028 |
| PRUNE2 | 14.5 ± 7.9 | 42.4 ± 17.6 | <0.001 | 0.788 (0.623–0.996) | 0.047 |
Data are shown as mean ± SD; a p-value calculated using the t-test; b p-value calculated using logistic regression for multivariate analysis.